S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin

Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01120262

Enrollment

545

Registered

2010-05-10

Start date

2010-02-28

Completion date

2010-07-31

Last updated

2016-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

recurrent prostate cancer, stage IV prostate cancer

Brief summary

RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin.

Detailed description

OBJECTIVES: * To test the association between serum PSA response (\< 4 ng/mL) at 7 months with inherited variability of germline single nucleotide polymorphisms, in a set of candidate genes, in patients with metastatic prostate cancer treated with combination induction androgen-deprivation therapy comprising bicalutamide and goserelin. OUTLINE: DNA extracted from whole blood or serum samples is analyzed for inherited variability of germline single nucleotide polymorphisms.

Interventions

GENETICgene expression analysis

GENETICpolymorphism analysis

OTHERlaboratory biomarker analysis

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosed with metastatic prostate cancer * Accrued to SWOG-9346 and received androgen-deprivation therapy (ADT) * Must have serum PSA values from the beginning to the end of 8 courses of ADT * Must have whole blood or serum samples available PATIENT CHARACTERISTICS: * Caucasian and African-American participants PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Serum PSA values at 7 months	7 months
Role of genetic variation in response to therapy	baseline

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026